The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.

@article{Keizman2011TheCO,
  title={The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.},
  author={Daniel Keizman and Peng Huang and Emmanuel S Antonarakis and Victoria W Sinibaldi and Michael Anthony Carducci and Samuel R Denmeade and Jenny Jane Kim and Janet Ruth Walczak and Mario A. Eisenberger},
  journal={The Prostate},
  year={2011},
  volume={71 15},
  pages={1608-15}
}
BACKGROUND We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. METHODS Data were retrospectively analyzed in 96 patients with biochemically relapsed prostate cancer (BRPC) treated with IAD since 1995. IAD consisted of LHRH-agonists ± antiandrogen given usually at PSA threshold (ng/ml) of 10-20, for 6-9 months. Cycles were repeated until the development of… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…